Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies

Hakan Inan, Shuqi Wang, Fatih Inci, Murat Baday, Richard Zangar, Sailaja Kesiraju, Karen Anderson, Brian T. Cunningham, Utkan Demirci

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Human Papillomavirus (HPV) infection has been recognized as the main etiologic factor in the development of various cancers including penile, vulva, oropharyngeal and cervical cancers. In the development of cancer, persistent HPV infections induce E6 and E7 oncoproteins, which promote cell proliferation and carcinogenesis resulting elevated levels of host antibodies (e.g., anti-HPV16 E7 antibody). Currently, these cancers are clinically diagnosed using invasive biopsy-based tests, which are performed only in centralized labs by experienced clinical staff using time-consuming and expensive tools and technologies. Therefore, these obstacles constrain their utilization at primary care clinics and in remote settings, where resources are limited. Here, we present a rapid, inexpensive, reliable, easy-to-use, customized immunoassay platform following a microfluidic filter device to detect and quantify anti-HPV16 E7 antibodies from whole blood as a non-invasive assisting technology for diagnosis of HPV-associated malignancies, especially, at primary healthcare and remote settings. The platform can detect and quantify anti-HPV16 E7 antibody down to 2.87 ng/mL. We further validated our immunoassay in clinical patient samples and it provided significantly high responses as compared to control samples. Thus, it can be potentially implemented as a pretesting tool to identify high-risk groups for broad monitoring of HPV-associated cancers in resource-constrained settings.

Original languageEnglish (US)
Article number3322
JournalScientific Reports
Volume7
Issue number1
DOIs
StatePublished - Dec 1 2017

Fingerprint

Tumor Biomarkers
Papillomavirus Infections
Lab-On-A-Chip Devices
Neoplasms
Immunoassay
Antibodies
Primary Health Care
Penile Neoplasms
Vulvar Neoplasms
Oropharyngeal Neoplasms
Technology
Oncogene Proteins
Uterine Cervical Neoplasms
Anti-Idiotypic Antibodies
Carcinogenesis
Cell Proliferation
Biopsy

ASJC Scopus subject areas

  • General

Cite this

Inan, H., Wang, S., Inci, F., Baday, M., Zangar, R., Kesiraju, S., ... Demirci, U. (2017). Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies. Scientific Reports, 7(1), [3322]. https://doi.org/10.1038/s41598-017-02672-6

Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies. / Inan, Hakan; Wang, Shuqi; Inci, Fatih; Baday, Murat; Zangar, Richard; Kesiraju, Sailaja; Anderson, Karen; Cunningham, Brian T.; Demirci, Utkan.

In: Scientific Reports, Vol. 7, No. 1, 3322, 01.12.2017.

Research output: Contribution to journalArticle

Inan, H, Wang, S, Inci, F, Baday, M, Zangar, R, Kesiraju, S, Anderson, K, Cunningham, BT & Demirci, U 2017, 'Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies', Scientific Reports, vol. 7, no. 1, 3322. https://doi.org/10.1038/s41598-017-02672-6
Inan, Hakan ; Wang, Shuqi ; Inci, Fatih ; Baday, Murat ; Zangar, Richard ; Kesiraju, Sailaja ; Anderson, Karen ; Cunningham, Brian T. ; Demirci, Utkan. / Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{f76f8dc66ed34576b4c89dc6a26fb417,
title = "Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies",
abstract = "Human Papillomavirus (HPV) infection has been recognized as the main etiologic factor in the development of various cancers including penile, vulva, oropharyngeal and cervical cancers. In the development of cancer, persistent HPV infections induce E6 and E7 oncoproteins, which promote cell proliferation and carcinogenesis resulting elevated levels of host antibodies (e.g., anti-HPV16 E7 antibody). Currently, these cancers are clinically diagnosed using invasive biopsy-based tests, which are performed only in centralized labs by experienced clinical staff using time-consuming and expensive tools and technologies. Therefore, these obstacles constrain their utilization at primary care clinics and in remote settings, where resources are limited. Here, we present a rapid, inexpensive, reliable, easy-to-use, customized immunoassay platform following a microfluidic filter device to detect and quantify anti-HPV16 E7 antibodies from whole blood as a non-invasive assisting technology for diagnosis of HPV-associated malignancies, especially, at primary healthcare and remote settings. The platform can detect and quantify anti-HPV16 E7 antibody down to 2.87 ng/mL. We further validated our immunoassay in clinical patient samples and it provided significantly high responses as compared to control samples. Thus, it can be potentially implemented as a pretesting tool to identify high-risk groups for broad monitoring of HPV-associated cancers in resource-constrained settings.",
author = "Hakan Inan and Shuqi Wang and Fatih Inci and Murat Baday and Richard Zangar and Sailaja Kesiraju and Karen Anderson and Cunningham, {Brian T.} and Utkan Demirci",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-02672-6",
language = "English (US)",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies

AU - Inan, Hakan

AU - Wang, Shuqi

AU - Inci, Fatih

AU - Baday, Murat

AU - Zangar, Richard

AU - Kesiraju, Sailaja

AU - Anderson, Karen

AU - Cunningham, Brian T.

AU - Demirci, Utkan

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Human Papillomavirus (HPV) infection has been recognized as the main etiologic factor in the development of various cancers including penile, vulva, oropharyngeal and cervical cancers. In the development of cancer, persistent HPV infections induce E6 and E7 oncoproteins, which promote cell proliferation and carcinogenesis resulting elevated levels of host antibodies (e.g., anti-HPV16 E7 antibody). Currently, these cancers are clinically diagnosed using invasive biopsy-based tests, which are performed only in centralized labs by experienced clinical staff using time-consuming and expensive tools and technologies. Therefore, these obstacles constrain their utilization at primary care clinics and in remote settings, where resources are limited. Here, we present a rapid, inexpensive, reliable, easy-to-use, customized immunoassay platform following a microfluidic filter device to detect and quantify anti-HPV16 E7 antibodies from whole blood as a non-invasive assisting technology for diagnosis of HPV-associated malignancies, especially, at primary healthcare and remote settings. The platform can detect and quantify anti-HPV16 E7 antibody down to 2.87 ng/mL. We further validated our immunoassay in clinical patient samples and it provided significantly high responses as compared to control samples. Thus, it can be potentially implemented as a pretesting tool to identify high-risk groups for broad monitoring of HPV-associated cancers in resource-constrained settings.

AB - Human Papillomavirus (HPV) infection has been recognized as the main etiologic factor in the development of various cancers including penile, vulva, oropharyngeal and cervical cancers. In the development of cancer, persistent HPV infections induce E6 and E7 oncoproteins, which promote cell proliferation and carcinogenesis resulting elevated levels of host antibodies (e.g., anti-HPV16 E7 antibody). Currently, these cancers are clinically diagnosed using invasive biopsy-based tests, which are performed only in centralized labs by experienced clinical staff using time-consuming and expensive tools and technologies. Therefore, these obstacles constrain their utilization at primary care clinics and in remote settings, where resources are limited. Here, we present a rapid, inexpensive, reliable, easy-to-use, customized immunoassay platform following a microfluidic filter device to detect and quantify anti-HPV16 E7 antibodies from whole blood as a non-invasive assisting technology for diagnosis of HPV-associated malignancies, especially, at primary healthcare and remote settings. The platform can detect and quantify anti-HPV16 E7 antibody down to 2.87 ng/mL. We further validated our immunoassay in clinical patient samples and it provided significantly high responses as compared to control samples. Thus, it can be potentially implemented as a pretesting tool to identify high-risk groups for broad monitoring of HPV-associated cancers in resource-constrained settings.

UR - http://www.scopus.com/inward/record.url?scp=85020703642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020703642&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-02672-6

DO - 10.1038/s41598-017-02672-6

M3 - Article

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 3322

ER -